Berita Kesehatan
Prevalence and Recovery of Adrenal Insufficiency in Steroid-Dependent Asthma Patients Receiving Biologic Therapy
Kamis, 15 Okt 2020 12:43:39

Asthma is a complex and heterogeneous inflammatory disease of the airways. Regular inhaled corticosteroid (ICS) therapy suppresses airway inflammation and treats asthma symptoms sufficiently in most patients. However, a small, but significant, proportion of patients with severe disease suffer from persistent daily symptoms and are reliant on oral corticosteroids (OCS), for short-term control in acute exacerbations, or as long-term maintenance therapy [1].

Footnotes

This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.

Conflict of interest: Dr. Nanzer reports personal fees from Teva, personal fees from Astra-Zeneca, personal fees from Napp, outside the submitted work.

Conflict of interest: A. Chowdhury has nothing to disclose.

Conflict of interest: A. Raheem has nothing to disclose.

Conflict of interest: C. Roxas has nothing to disclose.

Conflict of interest: M. Fernandes has nothing to disclose.

Conflict of interest: L. Thomson has nothing to disclose.

Conflict of interest: L. Green has nothing to disclose.

Conflict of interest: Dr. Dhariwal reports personal fees from Astra-Zeneca, outside the submitted work.

Conflict of interest: Dr. D'Ancona reports personal fees from Teva, personal fees from Astra Zeneca, personal fees from GSK, personal fees from Boehringer Ingelheim, personal fees from Chiesi, outside the submitted work.

Conflict of interest: Dr. Kent reports personal fees from Astra-Zeneca, personal fees from GSK, outside the submitted work.

Conflict of interest: Dr. Kelly has nothing to disclose.

Conflict of interest: Dr. Jackson reports personal fees from Astra-Zeneca, personal fees from GSK, personal fees from Teva, personal fees from Sanofi, personal fees from Novartis, outside the submitted work.

  • Received November 27, 2019.
  • Accepted March 11, 2020.